X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Mirapex (Pramipexole) – Treatment for Parkinson’s Disease

Yuvraj_pawp by Yuvraj_pawp
8th August 2014
in Europe, Projects

Mirapex (Pramipexole) is a medication indicated for Parkinson’s disease (PD). Developed by Boehringer Ingelheim, Mirapex was approved by the US Food and Drug Administration (FDA) in June 1997 and by the European Union (EU) in March 1998.

In 2006, Mirapex was approved by the FDA and the EU for the treatment of restless legs syndrome (RLS), a neurological disorder. In 2010, the FDA approved a once-daily formulation of Mirapex for the treatment of both early and advanced PD. It was previously approved by the EU for the same indication in October 2009.

Parkinson’s disease (PD)

PD is a chronic neurological disorder and is estimated to prevail in about 2% of population over the age of 65. PD is estimated to be the second biggest neurological illness in older patients, after Alzheimer’s disease. The disease can affect any person over the age of 40 with a risk of the disease increasing for people over the age of 80.

The disease occurs when there is a progressive loss of neurons or brain cells in the substantia nigra (a part of the brain). Substantia nigra produces the chemical dopamine, a type of molecule, which serves as a neurotransmitter. When the neurons die, the amount of dopamine transported to the striatum (an area of the brain which controls movement) decreases, resulting in problems with mobility.

“Parkinson’s disease is a chronic neurological disorder.”

PD is characterised by motor and non-motor symptoms, which worsen over time. Motor symptoms include tremors, muscle cramps, slowed motion or bradykinesia and poor balance. Non-motor symptoms include depression, anxiety, cognitive impairment and sleep disorders. These symptoms, however, can vary from one patient to another. There is no cure available for treating PD, although medications to treat the symptoms of the disease are accessible.

Mirapex – non-ergot D3 dopamine agonist

The main active ingredient in Mirapex is pramipexole dihydrochloride, which is a synthetic amino-benzothiazole derivative. Pramipexole is a DA receptor agonist, and has increased affinity and selectivity towards DA D2 receptors. The drug particularly has a high affinity for D3 receptor subtype.

In clinical trials, pramipexole bound to DA D2-class receptors in the brain. The highest affinity of the drug was towards the D3 binding sites. The drug did not have any affinity towards DA D1 subfamily and other types of neurotransmitters.

Mirapex clinical trials

The clinical development of Mirapex involved studies for the treatment of both early and advanced PD. A total of ten phase II/III trials were conducted as part of the development programme. FDA approval of the drug was based on three pivotal phase III studies, which included one study for advanced PD and two for early PD.

“The clinical development of Mirapex involved studies for the treatment of both early and advanced PD.”

The phase III trial for advanced PD, M/2730/0010, involved 360 patients and was conducted in the US and Canada. The study showed that Mirapex was effective in treating the mobility symptoms of PD when compared with the placebo. Another study, comparing pramipexole and bromocriptine with the placebo, was also conducted for treating advanced PD.

The first phase III trial for early PD, M/2730/0001, was conducted in the US and involved 335 patients. The second study, M/2730/0004, included 264 patients and was conducted in the US and Canada. In both the studies, Mirapex demonstrated significantly superior therapeutic efficacy.

The approval of Mirapex for the treatment of RLS was based on four placebo-controlled studies involving 1,000 patients. In the studies, when compared to placebo, Mirapex provided better relief from RLS symptoms to patients.

Mirapex’s approval for the treatment of both early and advanced PD was based on a randomised, placebo-controlled, three parallel group clinical trial. The study included 517 patients suffering from advanced PD. Mirapex showed superior efficacy compared with the placebo in the trial.

Marketing commentary

“By 2018, the market for PD treating drugs is expected to be worth more than $2.8bn.”

By 2018, the market for PD treating drugs is expected to be worth more than $2.8bn across those in the US, France, Germany, Italy, Spain, the UK and Japan. Mirapex’s new approval as a once-daily dose is expected to significantly boost its sales in the market.

In the US, however, generic competition and other established drugs are expected to affect the sales of the drug. Mirapex is, therefore, expected to generate only $400m in sales in the US.

Mirapex stands a better chance at generating profits by launching the drug in Europe where generic versions of the drug are not expected to be launched before 2011. This provides Boehringer enough time to establish the drug’s daily dose formulation in the market.

Tags: Europe
Previous Post

Selincro (nalmefene) - Treatment for Alcohol Dependence

Next Post

Eli Lilly Humalog Manufacturing Facility

Related Posts

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Gilead's drug remdesivir gets US FDA's emergency use authorisation for COVID-19
Europe

Gilead’s drug remdesivir gets US FDA’s emergency use authorisation for COVID-19

4th May 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Europe

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

17th August 2018
Next Post

Eli Lilly Humalog Manufacturing Facility

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In